Wang Changjian, Zheng Zhikun, Wu Chuangyan, Zhang Dan, Wang Yangchenxi, Zhang Sheng, Wang Geng, Zhou Rui
Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Biol Ther. 2025 Dec;26(1):2547564. doi: 10.1080/15384047.2025.2547564. Epub 2025 Aug 16.
Adipose-derived exosomes (ADEs), a subtype of extracellular vesicles, are critical mediators of communication between adipose tissue and tumors, playing pivotal roles in cancer progression and therapeutic response. These nanoscale vesicles carry microRNAs, proteins, and lipids that influence tumor cell proliferation, migration, metastasis, and immune modulation. The dual functions of ADEs - both in promoting and suppressing tumorigenesis - are largely dependent on their cellular origin, molecular cargo, and the characteristics of the tumor microenvironment. Recent studies have identified ADEs as potential diagnostic biomarkers, therapeutic targets, and drug delivery platforms, offering promising avenues for precision oncology. However, significant challenges - such as biological heterogeneity, lack of standardization in production, concerns regarding efficacy and safety, and regulatory constraints - continue to hinder their clinical translation. This review aimed to explore the multifaceted roles of ADEs in cancer pathogenesis, their therapeutic potential, and current limitations, providing insights to guide future research and clinical applications.
脂肪来源的外泌体（ADEs）是细胞外囊泡的一种亚型，是脂肪组织与肿瘤之间通讯的关键介质，在癌症进展和治疗反应中发挥着关键作用。这些纳米级囊泡携带微小RNA、蛋白质和脂质，影响肿瘤细胞的增殖、迁移、转移和免疫调节。ADEs在促进和抑制肿瘤发生方面的双重功能在很大程度上取决于其细胞来源、分子货物以及肿瘤微环境的特征。最近的研究已将ADEs确定为潜在的诊断生物标志物、治疗靶点和药物递送平台，为精准肿瘤学提供了有前景的途径。然而，诸如生物异质性、生产缺乏标准化、对疗效和安全性的担忧以及监管限制等重大挑战继续阻碍它们的临床转化。本综述旨在探讨ADEs在癌症发病机制中的多方面作用、它们的治疗潜力和当前局限性，为指导未来研究和临床应用提供见解。
